C12Y 204/01038
Beta-n-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase
Official title: Beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase (2.4.1.38)
C12Y204/01038 (Beta-n-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase) appears on 25 US grants and 55 published applications in this corpus.
Search patents in C12Y- Granted patents
- 25
- Published applications
- 55
- Assignees
- 27
- Inventors
- 99
- Latest grant
- 23 Dec 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 1 |
| 2006 | 1 | 0 |
| 2007 | 0 | 1 |
| 2008 | 1 | 1 |
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 2 |
| 2012 | 1 | 0 |
| 2013 | 1 | 2 |
| 2014 | 3 | 1 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 2 |
| 2018 | 2 | 1 |
| 2019 | 0 | 3 |
| 2020 | 0 | 2 |
| 2021 | 1 | 2 |
| 2022 | 3 | 1 |
| 2023 | 3 | 13 |
| 2024 | 3 | 9 |
| 2025 | 6 | 7 |
| 2026 | 0 | 5 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Dual drug antibody-drug conjugates23 Dec 2025US 12,503,506 B2University of Georgia Research Foundation, Inc.
- Inhibitors of expression and/or function7 Oct 2025US 12,435,337 B2E-Therapeutics PLC
- In vivo synthesis of sialylated compounds5 Aug 2025US 12,378,589 B2Inbiose N.V.
- Fermentative production of oligosaccharides by total fermentation utilizing a mixed feedstock24 Jun 2025US 12,338,473 B2Chr. Hansen A/S
- Enhancing formation of milk oligosaccharides (HMOs) by modifying lactose import in the cell29 Apr 2025US 12,286,658 B2Dsm IP Assets B.V.
- Genetically modified udp-n-acetylgalactosamine producing cells16 Jul 2026US 2026/0201318 A1Dsm IP Assets B.V.
- Vivo synthesis of sialylated compounds14 May 2026US 2026/0132407 A1Inbiose N.V.
- Production of a mixture of neutral fucosylated oligosaccharides by a cell26 Feb 2026US 2026/0055436 A1Inbiose N.V.
- Enhancing formation of human milk oligosaccharides (hmos) by modifying lactose import in the cell15 Jan 2026US 2026/0015636 A1Dsm IP Assets B.V.
- Inhibitors of expression and/or function8 Jan 2026US 2026/0009036 A1E-Therapeutics PLC
Most cited
By later US patents
- Method for manufacturing glycoproteins having human-type glycosylation32US 7,388,081 B2DFB Biotech, Inc. · 2008
- Method for manufacturing glycoproteins having human-type glycosylation21US 6,998,267 B1The Dow Chemical Company · 2006
- Methods for modifying human antibodies by glycan engineering12US 10,087,236 B2Academia Sinica · 2018
- Method for manufacturing glycoproteins having human-type glycosylation9US 8,241,909 B2Phyton Holdings, LLC · 2012
- Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function5US 8,367,374 B2Roche Glycart AG · 2013